UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

Core Insights - Tevogen Bio has developed a significant asset portfolio since its founding in 2020 while maintaining expenditures under $40 million, which is considerably lower than the industry average [1][3] - The company focuses on off-the-shelf, genetically unmodified T cell therapeutics aimed at treating infectious diseases and cancers, emphasizing a disciplined and sustainable business model [2][4] - Tevogen's leadership is committed to preserving shareholder value while navigating the need for capital, with potential equity dilution from warrant conversion at a strike price of $11.50 per share, which could yield over $200 million [1][3] Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company utilizing CD8+ cytotoxic T lymphocytes to develop precision T cell therapies for various diseases, addressing significant unmet medical needs [4][5] - The company has reported positive safety data from its proof-of-concept clinical trials and owns key intellectual property assets, including three granted patents and numerous pending patents [4] - Tevogen's leadership believes that accessible personalized therapeutics represent the next frontier in medicine, necessitating innovative business models to sustain medical advancements [5]